[1] Doan TN, Kong DC, Marshall C, et al. Modeling the impact of interventions against Acinetobacter baumannii transmission in intensive care units. Virulence, 2016; 7, 141-52. doi:  10.1080/21505594.2015.1076615
[2] Fattahian Y, Rasooli I, Mousavi Gargari SL, et al. Protection against Acinetobacter baumannii infection via its functional deprivation of biofilm-associated protein (Bap). Microb Pathog, 2011; 51, 402-6. doi:  10.1016/j.micpath.2011.09.004
[3] Zhang X, Yang T, Cao J, et al. Mucosal immunization with purified OmpA elicited protective immunity against infections caused by multidrug-resistant Acinetobacter baumannii. Microb Pathog, 2016; 96, 20-5. doi:  10.1016/j.micpath.2016.04.019
[4] Chiang MH, Sung WC, Lien SP, et al. Identification of novel vaccine candidates against Acinetobacter baumannii using reverse vaccinology. Hum Vaccin Immunother, 2015; 11, 1065-73. doi:  10.1080/21645515.2015.1010910
[5] Huang W, Yao Y, Wang S, et al. Immunization with a 22-kDa outer membrane protein elicits protective immunity to multidrug-resistant Acinetobacter baumannii. Sci Rep, 2016; 6, 20724. doi:  10.1038/srep20724
[6] Chen W. Current advances and challenges in the development of Acinetobacter vaccines. Hum Vaccin Immunother, 2015; 11, 2495-500. doi:  10.1080/21645515.2015.1052354
[7] Guo San-jun, Ren San, Xie Yong-en. Recombinant expression and purification of the OmpK outer membrane protein of Acinetobacter baumannii. Journal of Pathogen Biology, 2017; 12, 837-9. (In Chinese) http://www.en.cnki.com.cn/Article_en/CJFDTotal-ZISC201709006.htm
[8] Lee HY, Chen CL, Wu SR, et al. Risk factors and outcome analysis of Acinetobacter baumannii complex bacteremia in critical patients. Crit Care Med, 2014; 42, 1081-8. doi:  10.1097/CCM.0000000000000125
[9] Ballouz T, Aridi J, Afif C, et al. Risk Factors, Clinical presentation, and outcome of Acinetobacter baumannii bacteremia. Front Cell Infect Microbiol, 2017; 7, 156. doi:  10.3389/fcimb.2017.00156
[10] Badmasti F, Ajdary S, Bouzari S, et al. Immunological evaluation of OMV (PagL) + Bap (1-487aa) and AbOmpA (8-346aa) + Bap (1-487aa) as vaccine candidates against Acinetobacter baumannii spesis infection. Mol Immunol, 2015; 67, 552-8. doi:  10.1016/j.molimm.2015.07.031